QuidelOrtho Corporation/$QDEL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Ticker
$QDEL
Sector
Health
Primary listing
Employees
6,600
Headquarters
Website
QDEL Metrics
BasicAdvanced
$1.7B
-
-$6.92
-0.03
-
Price and volume
Market cap
$1.7B
Beta
-0.03
52-week high
$49.45
52-week low
$22.05
Average daily volume
1.8M
Financial strength
Current ratio
1.122
Quick ratio
0.374
Long term debt to equity
79.797
Total debt to equity
98.926
Interest coverage (TTM)
0.76%
Profitability
EBITDA (TTM)
588.7
Gross margin (TTM)
47.29%
Net profit margin (TTM)
-17.01%
Operating margin (TTM)
5.19%
Effective tax rate (TTM)
-14.29%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
1.39%
Return on equity (TTM)
-15.63%
Valuation
Price to revenue (TTM)
0.601
Price to book
0.59
Price to tangible book (TTM)
-2.85
Price to free cash flow (TTM)
310.757
Free cash flow yield (TTM)
0.32%
Free cash flow per share (TTM)
0.079
Growth
Revenue change (TTM)
-3.28%
Earnings per share change (TTM)
-75.10%
3-year revenue growth (CAGR)
-0.25%
10-year revenue growth (CAGR)
29.87%
3-year earnings per share growth (CAGR)
-32.14%
10-year earnings per share growth (CAGR)
51.52%
What the Analysts think about QDEL
Analyst ratings (Buy, Hold, Sell) for QuidelOrtho Corporation stock.
Bulls say / Bears say
QuidelOrtho's non-respiratory revenue remained stable at $2.3 billion in 2024, with Labs revenue growing by 4%, indicating resilience in core business areas. (quidelortho.com)
The company achieved $100 million in annualized cost savings through integration-related initiatives, positioning it for improved profitability. (quidelortho.com)
QuidelOrtho received 510(k) clearance for its Savanna multiplex molecular platform and HSV/VZV PCR assay, expanding its diagnostic product portfolio. (quidelortho.com)
The company reported a GAAP net loss of $2.03 billion in 2024, including a non-cash goodwill impairment charge of approximately $1.82 billion, raising concerns about asset valuation. (quidelortho.com)
Respiratory revenue declined by 30% in 2024 due to decreased COVID-19 and influenza revenues, highlighting vulnerability to pandemic-related demand fluctuations. (quidelortho.com)
GAAP diluted loss per share for the full-year 2024 was $30.16, compared to $0.15 in the prior year, indicating a significant deterioration in earnings performance. (quidelortho.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
QDEL Financial Performance
Revenues and expenses
QDEL Earnings Performance
Company profitability
QDEL News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for QuidelOrtho Corporation stock?
QuidelOrtho Corporation (QDEL) has a market cap of $1.7B as of August 08, 2025.
What is the P/E ratio for QuidelOrtho Corporation stock?
The price to earnings (P/E) ratio for QuidelOrtho Corporation (QDEL) stock is 0 as of August 08, 2025.
Does QuidelOrtho Corporation stock pay dividends?
No, QuidelOrtho Corporation (QDEL) stock does not pay dividends to its shareholders as of August 08, 2025.
When is the next QuidelOrtho Corporation dividend payment date?
QuidelOrtho Corporation (QDEL) stock does not pay dividends to its shareholders.
What is the beta indicator for QuidelOrtho Corporation?
QuidelOrtho Corporation (QDEL) has a beta rating of -0.03. This means that it has an inverse relation to market volatility.